- Home
- STRO vs PRQR Comparison
STRO vs PRQR Comparison
Compare STRO & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STRO
- PRQR
- Stock Information
- Founded
- STRO 2003
- PRQR 2012
- Country
- STRO United States
- PRQR Netherlands
- Employees
- STRO N/A
- PRQR N/A
- Industry
- STRO Biotechnology: Biological Products (No Diagnostic Substances)
- PRQR Biotechnology: Pharmaceutical Preparations
- Sector
- STRO Health Care
- PRQR Health Care
- Exchange
- STRO Nasdaq
- PRQR Nasdaq
- Market Cap
- STRO 74.3M
- PRQR 232.8M
- IPO Year
- STRO 2018
- PRQR 2014
- Fundamental
- Price
- STRO $0.86
- PRQR $2.04
- Analyst Decision
- STRO Hold
- PRQR Strong Buy
- Analyst Count
- STRO 7
- PRQR 8
- Target Price
- STRO $1.97
- PRQR $8.88
- AVG Volume (30 Days)
- STRO 514.4K
- PRQR 367.9K
- Earning Date
- STRO 11-12-2025
- PRQR 11-06-2025
- Dividend Yield
- STRO N/A
- PRQR N/A
- EPS Growth
- STRO N/A
- PRQR N/A
- EPS
- STRO N/A
- PRQR N/A
- Revenue
- STRO $104,473,000.00
- PRQR $20,129,184.00
- Revenue This Year
- STRO $65.42
- PRQR N/A
- Revenue Next Year
- STRO N/A
- PRQR N/A
- P/E Ratio
- STRO N/A
- PRQR N/A
- Revenue Growth
- STRO N/A
- PRQR 8.65
- 52 Week Low
- STRO $0.52
- PRQR $1.07
- 52 Week High
- STRO $4.60
- PRQR $4.62
- Technical
- Relative Strength Index (RSI)
- STRO 47.19
- PRQR 39.56
- Support Level
- STRO $0.85
- PRQR $1.91
- Resistance Level
- STRO $1.01
- PRQR $2.50
- Average True Range (ATR)
- STRO 0.09
- PRQR 0.15
- MACD
- STRO -0.01
- PRQR -0.04
- Stochastic Oscillator
- STRO 7.64
- PRQR 17.80
About STRO Sutro Biopharma Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.